{"id":"NCT02446743","sponsor":"GlaxoSmithKline","briefTitle":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","officialTitle":"A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-17","primaryCompletion":"2016-09-23","completion":"2016-09-23","firstPosted":"2015-05-18","resultsPosted":"2017-12-13","lastUpdate":"2018-11-08"},"enrollment":531,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Meningococcal"],"interventions":[{"type":"BIOLOGICAL","name":"rMenB+OMV NZ (Meningococcal (Group B) multi component recombinant adsorbed vaccine)","otherNames":[]}],"arms":[{"label":"Group 3B","type":"EXPERIMENTAL"},{"label":"Group B_0_1","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose/aim of this study is to assess 1) the long-term persistence (4 to 7.5 years after the last dose) of bactericidal activity following primary vaccination with rMenB+OMV NZ in adolescents \\[who previously participated in parent studies V72\\_41 (NCT0142384) and V72P10 (NCT00661713)\\] and 2) the kinetics of immune response following booster vaccination with rMenB+OMV NZ","primaryOutcome":{"measure":"Percentage of Subjects With Human Serum Bactericidal Activity (hSBA)≥1:4","timeFrame":"Group 3B: Day 1 (prior to booster dose); Group B_0_1: Day 1 (prior to first dose).","effectByArm":[{"arm":"Group 3B (V72_41)","deltaMin":84,"sd":null},{"arm":"Group 3B (V72P10)","deltaMin":84,"sd":null},{"arm":"Group 3B","deltaMin":84,"sd":null},{"arm":"Group B_0_1 (V72_41)","deltaMin":7,"sd":null},{"arm":"Group B_0_1 (V72P10)","deltaMin":24,"sd":null},{"arm":"Group B_0_1","deltaMin":17,"sd":null}],"pValues":[{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG004","p":null},{"comp":"OG002 vs OG005","p":null},{"comp":"OG000 vs OG003","p":null},{"comp":"OG001 vs OG004","p":null},{"comp":"OG002 vs OG005","p":null}]},"eligibility":{"minAge":"15 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":12,"countries":["Australia","Canada","Chile"]},"refs":{"pmids":["30691980"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":275},"commonTop":["Injectioon site pain","Injection site erythema","Fatigue","Headache","Injection site induration"]}}